Role of TLR signaling in francisella tularensis-LPS-induced, antibody-mediated protection against francisella tularensis challenge

Journal of Leukocyte Biology

Volumn 90, Issue 4, 2011, Pages 787-797

  Cole, Leah E ^a   Mann, Barbara J ^c   Shirey, Kari Ann ^a   Richard, Katharina ^a   Yang, Yang ^d   Gearhart, Patricia J ^e   Chesko, Kirsty L ^b   Viscardi, Rose M ^b   Vogel, Stefanie N ^a  

^a Departments of Microbiology and Immunology   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Adjuvants; Antibodies; B cells; Bacterial infection; Macrophage activation; Vaccination

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; FLAGELLIN; FRANCISELLA TULARENSIS LIPOPOLYSACCHARIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; CELL DIFFERENTIATION; ESCHERICHIA COLI; FEMALE; FRANCISELLA TULARENSIS; FRANCISELLA TULARENSIS LIVE VACCINE STRAIN; IMMUNIZATION; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TULAREMIA;

ANIMALS; ANTIBODIES, BACTERIAL; FEMALE; FRANCISELLA TULARENSIS; LIPOPOLYSACCHARIDES; MICE; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TULAREMIA;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; FRANCISELLA; FRANCISELLA TULARENSIS; MUS;

EID: 80053360280     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0111014     Document Type: Article

References (76)

1. Saslaw, S., Eigelsbach, H. T., Wilson, H. E., Prior, J. A., Carhart, S. (1961) Tularemia vaccine study. I. Intracutaneous challenge. Arch. Intern. Med. 107, 689-701.
2. Saslaw, S., Eigelsbach, H. T., Prior, J. A., Wilson, H. E., Carhart, S. (1961) Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med. 107, 702-714.
3. Christopher, G. W., Cieslak, T. J., Pavlin, J. A., Eitzen Jr., E. M. (1997) Biological warfare. A historical perspective. JAMA 278, 412-417.
4. Dennis, D. T., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Friedlander, A. M., Hauer, J., Layton, M., Lillibridge, S. R., McDade, J. E., Osterholm, M. T., O'Toole, T., Parker, G., Perl, T. M., Russell, P. K., Tonat, K. (2001) Tularemia as a biological weapon: medical and public health management. JAMA 285, 2763-2773.
5. Harris, S. (1992) Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann. N. Y. Acad. Sci. 666, 21-52.
6. Keim, P., Johansson, A., Wagner, D. M. (2007) Molecular epidemiology, evolution, and ecology of Francisella. Ann. N. Y. Acad. Sci. 1105, 30-66.
7. Burke, D. S. (1977) Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratoryacquired tularemia. J. Infect. Dis. 135, 55-60.
8. Petrosino, J. F., Xiang, Q., Karpathy, S. E., Jiang, H., Yerrapragada, S., Liu, Y., Gioia, J., Hemphill, L., Gonzalez, A., Raghavan, T. M., Uzman, A., Fox, G. E., Highlander, S., Reichard, M., Morton, R. J., Clinkenbeard, K. D., Weinstock, G. M. (2006) Chromosome rearrangement and diversification of Francisella tularensis revealed by the type B (OSU18) genome sequence. J. Bacteriol. 188, 6977-6985.
9. Titball, R. W., Petrosino, J. F. (2007) Francisella tularensis genomics and proteomics. Ann. N. Y. Acad. Sci. 1105, 98-121.
10. Eigelsbach, H. T., Downs, C. M. (1961) Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J. Immunol. 87, 415-425.
11. Hartley, G., Taylor, R., Prior, J., Newstead, S., Hitchen, P. G., Morris, H. R., Dell, A., Titball, R. W. (2006) Grey variants of the live vaccine strain of Francisella tularensis lack lipopolysaccharide O-antigen, show reduced ability to survive in macrophages and do not induce protective immunity in mice. Vaccine 24, 989-996.
12. Hornick, R. B., Eigelsbach, H. T. (1966) Aerogenic immunization of man with live tularemia vaccine. Bacteriol. Rev. 30, 532-538.
13. McCrumb, F. R. (1961) Aerosol infection of man with Pasteurella tularensis. Bacteriol. Rev. 25, 262-267.
14. Tärnvik, A. (1989) Nature of protective immunity to Francisella tularensis. Rev. Infect. Dis. 11, 440-451.
15. Elkins, K. L., Cowley, S. C., Bosio, C. M. (2003) Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect. 5, 135-142.
16. Cole, L. E., Elkins, K. L., Michalek, S. M., Qureshi, N., Eaton, L. J., Rallabhandi, P., Cuesta, N., Vogel, S. N. (2006) Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity. J. Immunol. 176, 6888-6899.
17. Cole, L. E., Yang, Y., Elkins, K. L., Fernandez, E. T., Qureshi, N., Shlomchik, M. J., Herzenberg, L. A., Vogel, S. N. (2009) Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc. Natl. Acad. Sci. USA 106, 4343-4348.
18. Dreisbach, V. C., Cowley, S., Elkins, K. L. (2000) Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and γ interferon. Infect. Immun. 68, 1988-1996.
19. Cole, L. E., Shirey, K. A., Barry, E., Santiago, A., Rallabhandi, P., Elkins, K. L., Puche, A. C., Michalek, S. M., Vogel, S. N. (2007) Toll-like receptor 2-mediated signaling requirements for Francisella tularensis live vaccine strain infection of murine macrophages. Infect. Immun. 75, 4127-4137.
20. Rathinam, V. A., Jiang, Z., Waggoner, S. N., Sharma, S., Cole, L. E., Waggoner, L., Vanaja, S. K., Monks, B. G., Ganesan, S., Latz, E., Hornung, V., Vogel, S. N., Szomolanyi-Tsuda, E., Fitzgerald, K. A. (2010) The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat. Immunol. 11, 395-402.
21. Hayashi, F., Smith, K. D., Ozinsky, A., Hawn, T. R., Goolett, D. R., Eng, J. K., Akira, S., Underhill, D. M., Aderem A. (2001) The innate immune response to bacerial flagellin is mediated by Toll-like receptor 5. Nature 410, 1099-1103.
22. Yu, Y., Zeng, H., Vijay-Kumar, M., Neish, A. S., Merlin, D., Sitaraman, S. V., Gerwitz, A. T. (2004) STAT signaling underlies difference between flagellin-induced and tumor necrosis factor-α-induced epithelial gene expression. J. Biol. Chem. 279, 35210-35218.
23. Shirey, K. A., Cole, L. E., Keegan, A. D., Vogel, S. N. (2008) Francisella tularensis live vaccine strain induces macropahge alternative activation as a survival mechanism. J. Immunol. 181, 4159-4167.
24. Kim, T. W., Staschke, K., Bulek, K., Yao, J., Peters, K., Oh, K. H., Vandenburg, Y., Xiao, H., Qian, W., Hamilton, T., Min, B., Sen, G., Gilmour, R., Li, X. (2007) A critical role for IRAK4 kinase activity in Toll-like receptor- mediated innate immunity. J. Exp. Med. 204, 1025-1036.
25. Vijay-Kumar, M., Carvalho, F. A., Aitken, J. D., Fifadara, N. H., Gewritz, A. T. (2010) TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin. Eur. J. Immunol. 40, 3528-3534.
26. Elkins, K. L., Winegar, R. K., Nacy, C. A., Fortier, A. H. (1992) Introduction of Francisella tularensis at skin sites induces resistance to infection and generation of protective immunity. Microb. Pathog. 13, 417-421.
27. Santiago, A. E., Cole, L. E., Franco, A., Vogel, S. N., Levine, M. M., Barry, E. M. (2009) Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes. Vaccine 27, 2426-2436.
28. Baker, C. N., Hollis, D. G., Thornsberry, C. (1985) Antimicrobial susceptibility testing of Francisella tularensis with a modified Mueller-Hinton broth. J. Clin. Microbiol. 22, 212-215.
29. Fortier, A. H., Slayter, M. V., Ziemba, R., Meltzer, M. S., Nacy, C. A. (1991) Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect. Immun. 59, 2922-2928.
30. Elkins, K. L., Leiby, D. A., Winegar, R. K., Nacy, C. A., Fortier, A. H. (1992) Rapid generation of specific protective immunity to Francisella tularensis. Infect. Immun. 60, 4571-4577.
31. Katz, J., Zhang, P., Martin, M., Vogel, S. N., Michalek, S. M. (2006) Tolllike receptor 2 is required for inflammatory responses to Francisella tularensis LVS. Infect. Immun. 74, 2809-2816.
32. O'Neill, L. A., Bowie, A. G. (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signaling. Nat. Rev. Immunol. 7, 353-364.
33. Kawagoe, T., Sato, S., Jung, A., Yamamoto, M., Matsui, K., Kato, H., Uematsu, S., Takeuchi, O., Akira, S. (2007) Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling. J. Exp. Med. 204, 1013-1024.
34. Ku, C. L., Picard, C., Erdos, M., Jeurissen, A., Bustamante, J., Puel, A., von Bernuth, H., Filipe-Santos, O., Chang, H. H., Lawrence, T., Raes, M., Marodi, L., Bossuyt, X., Casanova, J. L. (2007) IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J. Med. Genet. 44, 16-23.
35. Medvedev, A. E., Lentschat, A., Kuhns, D. G., Blanco, J. C., Salkowski, C., Zhang, S., Arditi, M., Gallin, J. I., Vogel, S. N. (2003) Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198, 521-531.
36. Turvey, S. E., Speert, D. P. (2007) Recurrent systemic pneumococcal disease and IRAK4 deficiency. Pediatr. Infect. Dis. J. 26, 1074.
37. Szabó, J., Dobay, O., Erdos, M., Borbely, A., Rozgonyi, F., Marodi, L. (2007) Recurrent infection with genetically identical pneumococcal isolates in a patient with interleukin-1 receptor-associated kinase-4 deficiency. J. Med. Microbiol. 56, 863-865.
38. Picard, C., Puel, A., Bonnet, M., Ku, C. L., Bustamante, J., Yang, K., Soudais, C., Dupuis, S., Feinberg, J., Fieschi, C., et al. (2003) Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299, 2076-2079.
39. Rhinehart-Jones, T. R., Fortier, A. H., Elkins, K. L. (1994) Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host γ interferon and T cells. Infect. Immun. 62, 3129-3137.
40. Kirimanjeswara, G. S., Golden, J. M., Bakshi, C. S., Metzger, D. W. (2007) Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J. Immunol. 179, 532-539.
41. Fulop, M., Mastroeni, P., Green, M., Titball, R. W. (2001) Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 19, 4465-4472.
42. Savitt, A. G., Mena-Taboada, P., Monsalve, G., Benach, J. L. (2009) Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy. Clin. Vaccine Immunol. 16, 414-422.
43. Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y., Honjo, T. (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102, 553-563.
44. Janeway, C., Travers, P., Walport, M., Shlomchik, M. (2004) Immunobiology, 6th ed., Garland Science, New York, NY, USA.
45. Persing, D. H., Coler, R. N., Lacy, M. J., Johnson, D. A., Baldridge, J. R., Hershberg, R. M., Reed, S. G. (2002) Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10, S32-S37.
46. Evans, J. T., Cluff, C. W., Johnson, D. A., Lacy, M. J., Persing, D. H., Baldridge, J. R. (2003) Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines 2, 219-229.
47. Baldridge, J. R., McGowan, P., Evans, J. T., Cluff, C., Mossman, S., Johnson, D., Persing, D. (2004) Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin. Biol. Ther. 4, 1129-1138.
48. Baldridge, J. R., Crane, R. T. (1999) Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 19, 103-107.
49. Henricson, B. E., Benjamin, W. R., Vogel, S. N. (1990) Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect. Immun. 58, 2429-2437.
50. Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R., Mitchell, T. C. (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316, 1628-1632.
51. Yang, Y., Tung, J. W., Ghosn, E. E., Herzenberg, L. A., Herzenberg, L. A. (2007) Division and differentiation of natural antibody-producing cells in mouse spleen. Proc. Natl. Acad. Sci. USA 104, 4542-4546.
52. Gordon, S., Martinez, F. O. (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32, 593-604.
53. Conlan, J. W., Vinogradov, E., Monteiro, M. A., Perry, M. B. (2003) Mice intradermally-inoculated with the intact lipopolysaccharide, but not the lipid A or O-chain, from Francisella tularensis LVS rapidly acquire varying degrees of enhanced resistance against systemic or aerogenic challenge with virulent strains of the pathogen. Microb. Pathog. 34, 39-45.
54. Rozak, D. A., Gelhaus, H. C., Smith, M., Zadeh, M., Huzella, L., Waag, D., Adamovicz, J. J. (2010) CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols. J. Immune Based Ther. Vaccines 8, 2.
55. Elkins, K. L., Rhinehart-Jones, T. R., Stibitz, S., Conover, J. S., Klinman, D. M. (1999) Bacterial DNA containing CpG motifs stimulates lymphocyte- dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162, 2291-2298.
56. Waag, D. M., McCluskie, M. J., Zhang, N., Krieg, A. M. (2006) A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect. Immun. 74, 1944-1948.
57. Wongratanacheewin, S., Kespichayawattana, W., Intachote, P., Pichyangkul, S., Sermswan, R. W., Krieg, A. M., Sirisinha, S. (2004) Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect. Immun. 72, 4494-4502.
58. Lembo, A., Pelletier, M., Iyer, R., Timko, M., Dudda, J. C., West, T. E., Wilson, C. B., Hajjar, A. M., Skerrett, S. J. (2008) Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J. Immunol. 180, 7574-7581.
59. Pyles, R. B., Jezek, G. E., Eaves-Pyles, T. D. (2010) Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection. Infect. Immun. 78, 1700-1710.
60. Malik, M., Bakshi, C. S., Sahay, B., Shah, A., Lotz, S. A., Sellati, T. J. (2006) Toll-like receptor 2 is required for control of pulmonary infection with Francisella tularensis. Infect. Immun. 74, 3657-3662.
61. Cole, L. E., Laird, M. H., Seekatz, A., Santiago, A., Jiang, Z., Barry, E., Shirey, K. A., Fitzgerald, K. A., Vogel, S. N. (2010) Phagosomal retention of Francisella tularensis results in TIRAP/Mal-independent TLR2 signaling. J. Leukoc. Biol. 87, 275-281.
62. Blander, J. M., Medzhitov, R. (2004) Regulation of phagosome maturation by signals from Toll-like receptors. Science 304, 1014-1018.
63. Clemens, D. L., Lee, B. Y., Horwitz, M. A. (2005) Francisella tularensis enters macrophages via a novel process involving pseudopod loops. Infect. Immun. 73, 5892-5902.
64. Green, S. J., Nacy, C. A., Schreiber, R. D., Granger, D. L., Crawford, R. M., Meltzer, M. S., Fortier, A. H. (1993) Neutralization of γ interferon and tumor necrosis factor α blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect. Immun. 61, 689-698.
65. Anthony, L. S., Morrissey, P. J., Nano, F. E. (1992) Growth inhibition of Francisella tularensis live vaccine strain by IFN-γ-activated macrophages is mediated by reactive nitrogen intermediates derived from L-arginine metabolism. J. Immunol. 148, 1829-1834.
66. Fortier, A. H., Polsinelli, T., Green, S. J., Nacy, C. A. (1992) Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules. Infect. Immun. 60, 817-825.
67. Wang, J., Wakeham, J., Harkness, R., Xing, Z. (1999) Macrophages are a significant source of type 1 cytokines during mycobacterial infection. J. Clin. Invest. 103, 1023-1029.
68. Atkinson, S., Valadas, E., Smith, S. M., Lukey, P. T., Dockrell, H. M. (2000) Monocyte-derived macrophage cytokine responses induced by M. bovis BCG. Tuber. Lung Dis. 80, 197-207.
69. Cole, L. E., Santiago, A., Barry, E., Kang, T. J., Shirey, K. A., Roberts, Z. J., Elkins, K. L., Cross, A. S., Vogel, S. N. (2008) Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways. J. Immunol. 180, 6885-6891.
70. Henry, T., Kirimanjeswara, G. S., Ruby, T., Jones, J. W., Peng, K., Perret, M., Ho, L., Sauer, J. D., Iwakura, Y., Metzger, D. W., Monack, D. M. (2010) Type I IFN signaling constrains IL-17A/F secretion by γδ T cells during bacterial infections. J. Immunol. 184, 3755-3767.
71. Thomas, K. E., Galligan, C. L., Newman, R. D., Fish, E. N., Vogel, S. N. (2006) Contribution of interferon- to the murine macrophage response to the Toll-like receptor 4 agonist, lipopolysaccharide. J. Biol. Chem. 281, 31119-31130.
72. Gunn, J. S., Ernst, R. K. (2007) The structure and function of Francisella lipopolysaccharide. Ann. N. Y. Acad. Sci. 1105, 202-218.
73. Prior, J. L., Prior, R. G., Hitchen, P. G., Diaper, H., Griffin, K. F., Morris, H. R., Dell, A., Titball, R. W. (2003) Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis. J. Med. Microbiol. 52, 845-851.
74. Thirumalapura, N. R., Goad, D. W., Mort, A., Morton, R. J., Clarke, J., Malayer, J. (2005) Structural analysis of the O-antigen of Francisella tularensis subspecies tularensis strain OSU 10. J. Med. Microbiol. 54, 693-695.
75. Crane, D. D., Warner, S. L., Bosio, C. M. (2009) A novel role for plasminmediated degradation of opsonizing antibody in the evasion of host immunity by virulent, but not attenuated, Francisella tularensis. J. Immunol. 183, 4593-4600.
76. Medvedev, A. E., Sabroe, I., Hasday, J. D., Vogel, S. N. (2006) Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. J. Endotoxin Res. 12, 133-150.